Oxford, UK – 16 October, 2014 – e-Therapeutics plc (AIM: ETX), the drug discovery and development company, is pleased to announce it is appointing Sean Nicolson, aged 48, to the Board of Directors as an Executive Director. The appointment is expected to become effective in 2015 following Mr. Nicolson’s resignation from Bond Dickinson LLP and the fulfilment of his existing contractual obligations.
Sean has over 22 years’ experience as a solicitor. He is currently an equity partner in the corporate team of Bond Dickinson LLP, a position he has held for 17 years. He has many years’ experience of advising companies in the technology sector on IPOs, venture capital and private equity fundraisings, mergers and acquisitions, joint ventures and corporate governance. He currently serves as Company Secretary of e-Therapeutics and its subsidiary and has advised the Company since its incorporation.
Commenting on the appointment, Professor Malcolm Young, CEO of e-Therapeutics, said:
“We are delighted to welcome Sean Nicolson to the Board. Sean brings a wealth of knowledge and strong commercial skills. We intend to put his experience to good use as we continue to advance our drug development portfolio and apply our network pharmacology approach in drug discovery.”
Sean Nicolson - biography
Sean Nicolson is currently a director of Northern Canon (a registered charity), Prima Director Limited and Prima Secretary Limited. He is also a partner at both Bond Dickinson LLP and Monograph LLP.
Previously he has been a director of Bizdocs Limited, Bond Dickinson Financial Services Limited, Bond Dickinson Service Company Limited, Bond Dickinson Wealth Limited, Designed and Made, Dickinson Dees Financial Services Limited, mima friends (a registered charity) and Monograph Publishing Limited. He was also a director of BDK Investments Limited (“BDK”) from its incorporation on 8 March 2011 until 17 March 2011 and Badekabiner Limited (“Badekabiner”) from its incorporation on 11 March 2011 until his resignation on 7 April 2011. BDK and Badekabiner were Bond Dickinson shelf companies created for the benefit of clients of the firm. BDK and its subsidiary, Badekabiner, were subsequently placed into administration on 30 January 2012. BDK and Badekabiner were dormant companies throughout the periods in which Mr. Nicolson was a director. He was not involved in BDK’s or Badekabiner’s subsequent activities or their administration proceedings.
As a partner in a law firm, Mr. Nicolson is a director and has been a director during the past five years, of many of Bond Dickinson’s other shelf companies created for the use of the firm’s clients, amounting to 211 appointments in total. A full list of these appointments as a director is available at the following link http://www.rns-pdf.londonstockexchange.com/rns/4747U_-2014-10-16.pdf.
Mr. Nicolson currently holds 88,888 ordinary shares in e-Therapeutics, representing 0.03 per cent. of the Company’s issued share capital.
There are no other matters required to be disclosed in respect of this appointment under paragraph (g) of Schedule Two of the Aim Rules or AIM Rule17.
A further announcement will be made in due course to confirm the effective date of this appointment.
Notes to Editors
About e-Therapeutics plc
e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company’s discovery and development activity is currently focused in cancer and disorders of the nervous system.
e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.
Issued for and on behalf of e-Therapeutics by Instinctif Partners.
To contact the e-Therapeutics team at Instinctif Partners, email email@example.com
Melanie Toyne-SewellManaging Partner